SkylineDX’s predictive melanoma test secures FDA breakthrough designation
July 1, 2026
SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.
SkylineDX’s test stratifies cutaneous melanoma patients into metastatic risk categories to inform treatment decisions.
The comprehensive review in which this discovery was first made is published in Nature Reviews Bioengineering and was led by Giacomo Valle, assistant professor at Chalmers University of Technology in Sweden.
A collaborative research team led by National Yang Ming Chiao Tung University and National Taiwan University investigated the therapeutic potential of gene therapy administered after birth.
In a new study published in Cell Stem Cell, the researchers developed a patient-derived organoid platform to uncover how chronic pancreatitis develops at the molecular level and identify possible therapeutic strategies.
In the new study, the researchers show that METTL3 in breast cancer cells relocates from its usual location in the nucleus to the cytoplasm.
Researchers report encouraging early results from a first-in-human clinical trial led by Children’s National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors.
Biomedical engineers at Duke University have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel cells critical to retinal health for the first time.
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has been demonstrated by researchers at the University of Bath in the U.K.
A recent study found that a blood protein called GDF15, which is released when cells are under stress, could serve as one of the earliest warning signs of dementia.
BLOOMINGTON, Minn., June 30, 2026 /PRNewswire/ — Saluda Medical, Inc. (ASX: SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Saluda’s CAP24 paddle lead, allowing it to be marketed and sold in the U.S.